In:
Hepatology Research, Wiley, Vol. 48, No. 2 ( 2018-02), p. 184-192
Abstract:
To assess the efficacy and safety of telaprevir (TVR) when used in combination with natural human interferon‐β (IFN‐β) and ribavirin (RBV) for genotype 1 patients with depression compared to IFN‐β/RBV therapy in Japan. We also examined the efficacy of the TVR/IFN‐β/RBV therapy in treatment failure genotype 2 patients with depression. Methods For the genotype 1 patients, 30 patients received TVR (750 mg every 8 h) for 12 weeks combined with IFN‐β and RBV for 24 weeks (Group A), and 30 received IFN‐β and RBV for 48 weeks (Group B). For the genotype 2 patients, 14 patients were dosed only with the TVR‐based regimen. Results The sustained virologic response (SVR) rates for Group A and Group B were 63.3% and 20.0%, respectively ( P = 0.001, likelihood ratio test). The SVR rate for genotype 2 patients previously treated with pegylated IFN and/or RBV was 71.4%. No patient dropped out due to exacerbation of depression. The trend of platelet counts after the drugs were given was similar in the TVR/IFN‐β/RBV therapy group and the IFN‐β/RBV therapy group. Common resistance‐associated variants of TVR were identified in 4 of the 13 patients who did not achieve SVR. Conclusion This study showed that an addition of TVR to IFN‐β/RBV therapy raised SVR in previously treated and untreated genotype 1 patients and previously treated genotype 2 patients with chronic hepatitis C and depression.
Type of Medium:
Online Resource
ISSN:
1386-6346
,
1872-034X
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2006439-1
Permalink